Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition comprising effective amounts of pharmacologically active agents, wherein said pharmacologically active agents comprise:
(a) an anti-human Fas antibody having an apoptosis inducing activity, said anti-human Fas antibody being ~~monoclonal antibody CH11~~[[,]] monoclonal antibody HFE7A or a humanized antibody of ~~monoclonal antibody CH11 or~~ monoclonal antibody HFE7A; and
(b) a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity, said compound being methotrexate,
the relative amounts of said pharmacologically active agents (a) and (b) being such that said pharmacologically active agents (a) and (b) exhibit a synergistic apoptosis inducing activity.

Claims 2 and 3. (canceled)

Claim 4. (currently amended) The pharmaceutical composition according to claim 1, wherein said anti-human Fas antibody having apoptosis inducing activity is ~~an anti-human Fas~~ the monoclonal antibody HFE7A which is produced by a mouse-mouse hybridoma HFE7A (FERM BP-58280) ~~or a humanized antibody thereof~~.

Claims 5 to 12. (canceled)

Claim 13. (currently amended) A pharmaceutical composition in the form of a solution comprising effective amounts of pharmacologically active agents together with a diluent therefor, wherein said pharmacologically active agents comprise:
(a) an anti-human Fas antibody having apoptosis inducing activity ~~selected from the group consisting of a~~ which is monoclonal antibody ~~CH11 and~~ HFE7A, or a humanized antibody thereof in a concentration of 0.1 to 100 ng/ml; and
(b) methotrexate in a concentration of 0.05 to 5 nM,
the relative amounts of said active ingredients (a) and (b) being such that they exhibit a synergistic apoptosis inducing activity.

Claim 14. (currently amended) A method for the treatment of a disease selected from the group consisting of rheumatoid arthritis, chronic thyroiditis, allergic encephalitis, myasthenia gravis, hyperthyroidism, extreme insulin resistance in diabetes, rheumatic fever, human hemolytic anemias, granulocytopenias, thrombocytepenias and systemic lupus erythematosis comprising administering to a human in need thereof effective amounts of the following active ingredients:

(a) an anti-human Fas antibody having an apoptosis inducing activity, said anti-human Fas antibody being ~~monoclonal antibody CH11~~[[,]] monoclonal antibody HFE7A or a humanized antibody of ~~monoclonal antibody CH11 or~~ monoclonal antibody HFE7A; and

(b) a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity, said compound being methotrexate,

the relative amounts of the active ingredients (a) and (b) being administered such that said active ingredients (a) and (b) exhibit a synergistic apoptosis inducing activity.

Claims 15 to 17. (canceled)

Claim 18. (currently amended) The method according to claim 14, wherein said anti-human Fas antibody having apoptosis inducing activity is the monoclonal antibody HFE7A which is produced by a mouse-mouse hybridoma HFE7A (FERM BP-5828) ~~or a humanized antibody thereof~~.

Claims 19 to 26. (canceled)

Claim 27. (previously presented) The method according to claim 14, wherein the anti-human Fas antibody is administered in a daily dosage of 0.001 to 10 mg/kg and the compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity is administered in a daily dosage of 0.15 μg/kg to 0.15 mg/kg.

Claim 28. (currently amended) A method for the treatment of a disease selected from the group consisting of rheumatoid arthritis, chronic thyroiditis, allergic encephalitis, myasthenia gravis, hyperthyroidism, extreme insulin resistance in diabetes, rheumatic fever, human hemolytic anemias, granulocytopenias, thrombocytepenias and systemic lupus erythematosis comprising

administering to a human in need thereof effective amounts of a medicament in the form of a solution comprising pharmacologically active agents together with a diluent therefor, wherein said pharmacologically active agents comprise:

(a) an anti-human Fas antibody having apoptosis inducing activity selected from the group consisting of ~~monoclonal antibody CH11~~[[,]] monoclonal antibody HFE7A and a humanized antibody of ~~monoclonal antibody CH11 or~~ monoclonal antibody HFE7A, in a concentration of 0.1 to 100 ng/ml; and

(b) methotrexate at a concentration of 0.05 to 5 nM,

the relative amounts of said pharmacologically active agents (a) and (b) being such that said pharmacologically active agents (a) and (b) exhibit a synergistic apoptosis inducing activity.

Claims 29 to 43. (canceled)

Claim 44. (previously presented) The method according to claim 14, wherein said disease is rheumatoid arthritis.

Claim 45. (canceled)

Claim 46. (previously presented) The method according to claim 18, wherein said disease is rheumatoid arthritis.

Claim 47. (previously presented) The method according to claim 27, wherein said disease is rheumatoid arthritis.

Claim 48. (previously presented) The method according to claim 28, wherein said disease is rheumatoid arthritis.--

Claim 49. (new) The pharmaceutical composition according to claim 1, wherein said anti-human Fas antibody having apoptosis inducing activity is a humanized antibody of the monoclonal antibody HFE7A which is produced by a mouse-mouse hybridoma HFE7A (FERM BP-5828).

Claim 50. (new) The method according to claim 14, wherein said anti-human Fas antibody having apoptosis inducing activity is a humanized antibody of the monoclonal antibody HFE7A which is produced by a mouse-mouse hybridoma HFE7A (FERM BP-5828).

Claim 51. (new) The method according to claim 50, wherein said disease is rheumatoid arthritis.